ロード中...
Current treatment of atypical hemolytic uremic syndrome
Tremendous advances have been made in understanding the pathogenesis of atypical Hemolytic Uremic Syndrome (aHUS), an extremely rare disease. Insights into the molecular biology of aHUS resulted in rapid advances in treatment with eculizumab (Soliris(®), Alexion Pharmaceuticals Inc.). Historically,...
保存先:
| 主要な著者: | , , , |
|---|---|
| フォーマット: | Artigo |
| 言語: | Inglês |
| 出版事項: |
International Research and Cooperation Association for Bio & Socio-Sciences Advancement
2014
|
| 主題: | |
| オンライン･アクセス: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4204535/ https://ncbi.nlm.nih.gov/pubmed/25343125 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.5582/irdr.2014.01001 |
| タグ: |
タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!
|